Compare Lemonade Inc (LMND) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Zimmer Biomet Holdings Inc — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.7× Lemonade Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LMND | ZBH | |
|---|---|---|
Market Cap | $3.63B | $16.95B |
Volume | 1,544,794 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $96.57 | $103.98 |
52-Week Low | $43.91 | $79.58 |
Typical Hold Time | 27 Days | 89 Days |
Enterprise Value | $3.49B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LMND trades at $46.46, down 0.79% on the day, with a bearish technical signal and key resistance at $48. Revenue growth is strong, rising to $738 million in 2025, but the company remains unprofitable with a net margin of -22.43%. Recent news highlights expansion into new states and AI-driven efficiency gains, targeting EBITDA profitability by late 2026.
The outlook balances high growth potential against persistent losses. Analyst consensus is divided with a $67 price target suggesting upside, but execution risks and competitive pressures remain key concerns. The path to profitability is the critical catalyst for shareholder value.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
